Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.

被引：19
|
作者：
Juric, Dejan
Munster, Pamela N.
Campone, Mario
Ismail-Khan, Roohi
Garcia-Estevez, Laura
Hamilton, Erika Paige
Becerra, Carlos
De Boer, Richard H.
Hui, Rina
Goncalves, Anthony
Wang, Yingbo
Dhuria, Shyeilla V.
Kalimi, Ghulam H.
Lorenc, Karen Cristina Rodriguez
Mayer, Ingrid A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Inst Cancerol Ouest Rene Gauducheau, St Herblain, France
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL USA
[5] Ctr Integral Oncol Clara Campal, START Dept, Madrid, Spain
[6] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[7] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[8] Royal Melbourne Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[9] Westmead Hosp, Sydney, NSW, Australia
[10] Univ Sydney, Sydney, NSW, Australia
[11] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Vanderbilt Ingram Canc Ctr, Breast Canc Program, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
568
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase Ib study of ribociclib plus letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA
    Yap, Yoon Sim
    Ito, Yoshinori
    Suarez-Vizcarra, Jose
    Liu, Xiaochun
    Han, Yu
    Germa, Caroline
    Chiu, Joanne
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib 1 letrozole in hormone receptor-positive (HR1), HER2-negative (HER2-) advanced breast cancer (ABC)
    Spazzapan, S.
    Conte, P.
    Simoncini, E.
    Campone, M.
    Miller, M.
    Sonke, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
    Abraham, Jame
    Mechcatie, Elizabeth
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86
  • [25] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [26] Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment: MONALEESA-3
    Fasching, P. A.
    Jerusalem, G.
    Pivot, X.
    Martin, M.
    De Laurentiis, M.
    Blackwell, K.
    Esteva, F. J.
    Paquet-Luzy, T.
    Tang, Z.
    Lorenc, K. R.
    Slamon, D. J.
    CANCER RESEARCH, 2016, 76
  • [27] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [28] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [29] Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
    Bardia, Aditya
    Modi, Shanu
    Gregor, Mariana Chavez-Mac
    Kittaneh, Muaiad
    Marino, Alyssa J.
    Matano, Alessandro
    Bhansali, Suraj
    Hewes, Becker
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
    Ciruelos, E. M.
    Hamilton, E. P.
    Kim, S-B.
    Im, Y-H.
    Solis, E. Segui
    Saenz, J. A. Garcia
    Di Sanzo, A.
    Lizarbe, M. Dominguez
    Wasserman, T.
    Theall, K. P.
    Ibrahim, N. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S370 - S370
12345